EGFR and lung cancer: Another study showed that a combination of SAHA and tyrosine kinase inhibitors (afatinib and WZ4002, third generation of TKIs) overcame EGFR TKI resistance in lung cancer cells and decreased cell viability both in vivo and in vitro (Lee et al., 2015b).